CRTX Cortexyme, Inc. Stock Quote

CRTX [NASD]

Index	-	P/E	-	EPS (ttm)	-2.94	Insider Own	0.30%	Shs Outstand	29.77M	Perf Week	-6.74%
Market Cap	356.69M	Forward P/E	-	EPS next Y	-2.61	Insider Trans	-53.42%	Shs Float	20.09M	Perf Month	-10.95%
Income	-87.10M	PEG	-	EPS next Q	-0.51	Inst Own	64.10%	Short Float	39.52%	Perf Quarter	-88.64%
Sales	-	P/S	-	EPS this Y	-35.60%	Inst Trans	3.58%	Short Ratio	4.42	Perf Half Y	-70.92%
Book/sh	4.46	P/B	2.70	EPS next Y	1.00%	ROA	-51.80%	Target Price	64.57	Perf Year	-75.25%
Cash/sh	3.86	P/C	3.12	EPS next 5Y	18.30%	ROE	-57.70%	52W Range	11.79 - 121.98	Perf YTD	-56.70%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-90.14%	Beta	-
Dividend %	-	Quick Ratio	8.40	Sales past 5Y	-	Gross Margin	-	52W Low	2.03%	ATR	2.78
Employees	37	Current Ratio	8.40	Sales Q/Q	-	Oper. Margin	-	RSI (14)	17.34	Volatility	5.79% 10.73%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	0.00%	Profit Margin	-	Rel Volume	0.29	Prev Close	12.22
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	1.80M	Price	12.03
Recom	2.70	SMA20	-17.53%	SMA50	-77.12%	SMA200	-77.28%	Volume	524,631	Change	-1.55%

Oct-27-21

Downgrade

BofA Securities

Neutral → Underperform

$58 → $15

Apr-26-21

Resumed

Credit Suisse

Underperform

$14

Feb-17-21

Downgrade

Jefferies

Buy → Hold

$59 → $34

Dec-11-20

Initiated

Citigroup

Sell

$20

Jun-24-20

Initiated

H.C. Wainwright

Buy

$76

Jun-02-20

Initiated

Jefferies

Buy

$59

Jun-03-19

Initiated

JMP Securities

Mkt Outperform

$53

Jun-03-19

Initiated

Credit Suisse

Underperform

$14

Jun-03-19

Initiated

Canaccord Genuity

Buy

$42

Jun-03-19

Initiated

BofA/Merrill

Neutral

$28

Nov-23-21 08:00AM	Cortexyme to Present at 4th Annual Evercore ISI HealthCONx Conference on November 30th Business Wire
Nov-11-21 04:08PM	Cassava And Cortexyme Diverge Why One Alzheimer's Stock Is 'Back On Track' Investor's Business Daily -7.43%
12:54PM	Why Are Cortexyme Shares Falling Today? Benzinga
11:30AM	Cortexymes Atuzaginstat Slowed Cognitive Decline in Participants With Alzheimers Disease and P. Gingivalis Infection in Phase 2/3 GAIN Trial: Additional Top-line Data Presented at CTAD 2021 Business Wire
10:08AM	Cortexyme Stock Falls After Presenting More Data From Alzheimer's Trial Investing.com
Nov-05-21 08:16AM	Possible turnaround for Cortexyme, Inc. (NASDAQ:CRTX) insiders, still down US$1.8m after a US$3.5m shopping spree Simply Wall St.
Nov-04-21 08:00AM	Cortexyme to Present Additional Top-line GAIN Trial Results and Analysis at CTAD 2021 on November 11th Business Wire
04:33AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Cortexyme, Inc. - CRTX PR Newswire
02:39AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Cortexyme, Inc. - CRTX PR Newswire
Nov-03-21 11:15AM	Cortexyme, Inc. Investors: Company Investigated by the Portnoy Law Firm GlobeNewswire -5.77%
Nov-01-21 03:21PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Cortexyme, Inc. - CRTX GlobeNewswire +7.65%
Oct-29-21 06:23PM	Cortexyme Investor Alert: Kaplan Fox Investigates Potential Securities Fraud At Cortexyme, Inc. GlobeNewswire -7.43%
05:08PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Cortexyme, Inc. - CRTX Newsfile
Oct-28-21 10:00AM	Down 76%: Is Cortexyme Stock a Bargain? Motley Fool +5.55%
05:25AM	Cortexyme's Alzheimer's Drug Fails -- 2 Lessons for Investors Motley Fool
04:50AM	64 Biggest Movers From Yesterday Benzinga
Oct-27-21 10:50PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Cortexyme, Inc. - CRTX ACCESSWIRE -76.58%
04:05PM	Cortexyme Says There's A Caveat In Its Missed Alzheimer's Test But Shares Crash Investor's Business Daily
02:40PM	Mid-Afternoon Market Update: Nasdaq Surges Over 100 Points; Cortexyme Shares Plunge Benzinga
01:55PM	Why Cortexyme Shares Are Falling Benzinga
12:43PM	Here's Why Cortexyme Is Imploding on Wednesday Motley Fool
12:14PM	Mid-Day Market Update: Dow Falls Over 100 Points; Silicon Laboratories Shares Spike Higher Benzinga
12:00PM	44 Stocks Moving In Wednesday's Mid-Day Session Benzinga
12:00PM	Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Cortexyme, Inc. (CRTX) Investigation ACCESSWIRE
11:18AM	Why an Alzheimer's-focused biotech hoping to 'change the world' shed 70% of its value American City Business Journals
10:21AM	Mid-Morning Market Update: Markets Rise; Coca-Cola Tops Q3 Views Benzinga
10:20AM	Cortexyme's stock tumbles on failed clinical trial for Alzheimer's drug MarketWatch
07:09AM	28 Stocks Moving in Wednesday's Pre-Market Session Benzinga
Oct-26-21 04:01PM	Cortexyme Reports GAIN Trial Data Demonstrated Relationship Between Reduction of P. gingivalis Infection and Slowing of Alzheimers Disease Progression Business Wire
04:00PM	Cortexyme's Alzheimer's treatment fails to meet main goals in study Reuters
Oct-21-21 11:00AM	Why Cortexyme Thinks It Could Be Next In The Mega Alzheimer's Drug Market Investor's Business Daily
Oct-08-21 11:57AM	Notable Cortexyme Insider Trades $760K In Company Stock Benzinga
Sep-27-21 08:00AM	Cortexyme to Present Results from the GAIN Trial: A Phase 2/3 Study of Atuzaginstat in Mild to Moderate Alzheimers Disease at CTAD 2021 Business Wire
Sep-08-21 08:00AM	Cortexyme Expands Proprietary Development Pipeline with Initiation of Phase 1 Clinical Trial of COR588 Business Wire
Sep-07-21 08:00AM	Cortexyme to Present at H.C. Wainwright 23rd Annual Global Investment Conference on September 13th Business Wire
Aug-25-21 08:00AM	Cortexyme Presents New Data Demonstrating Evidence of P. Gingivalis Infection of the Central Nervous System in Alzheimers Disease at Annual Biomarkers for Alzheimers Disease Summit Business Wire
Aug-18-21 08:00AM	Cortexyme to Present at Annual Biomarkers for Alzheimers Disease Summit Business Wire
Aug-09-21 08:00AM	Cortexyme Provides Business Update and Reports Second Quarter 2021 Results Business Wire +47.32%
Aug-07-21 05:29AM	Companies Like Cortexyme (NASDAQ:CRTX) Are In A Position To Invest In Growth Simply Wall St.
Aug-04-21 08:00AM	Cortexyme to Present at Canaccord Genuity' s 41st Annual Growth Conference on August 11th Business Wire +10.83%
Jul-26-21 09:05AM	Cortexyme Presents Data Linking P. Gingivalis to Elevated Levels of Phospho-tau217 Reinforcing Evidence of Pathogen as Causative Agent of Alzheimers Disease at AAIC 2021 Business Wire -7.26%
Jul-23-21 08:00AM	Cortexyme Announces Lead 3CLpro Inhibitor for the Treatment of Coronavirus Infection Business Wire
Jul-22-21 08:00AM	Cortexyme to Present New Data at AAIC 2021 Business Wire +5.41%
Jul-21-21 08:00AM	Cortexyme Presents New Data Demonstrating Atuzaginstat Disrupts Biofilms and is Efficacious in Preclinical Models of Periodontal Disease at IADR 2021 Business Wire +5.92%
Jul-19-21 08:00AM	Cortexyme to Host Symposium at AAIC 2021 Business Wire
Jul-08-21 08:00AM	Cortexyme to Host Two-Part Key Opinion Leader Webinar Series on Atuzaginstat Business Wire +5.08%
Jun-13-21 02:20PM	Hedge Funds Are Dumping Cortexyme, Inc. (CRTX) Insider Monkey
Jun-01-21 08:00AM	Cortexyme Presents Updated Baseline Data from Complete Set of Participants Enrolled in Pivotal GAIN Trial at ASCP 2021 Annual Meeting Business Wire
May-26-21 08:00AM	Cortexyme to Present at Investor Conferences in June 2021 Business Wire +12.99%
May-10-21 08:00AM	Cortexyme Provides Business Update and Reports First Quarter 2021 Results Business Wire -9.81%
May-09-21 04:13AM	How Much Are Cortexyme, Inc. (NASDAQ:CRTX) Insiders Spending On Buying Shares? Simply Wall St.
May-04-21 08:00AM	Cortexyme to Present at the BofA Securities 2021 Healthcare Conference on May 11, 2021 Business Wire -7.96%
Mar-25-21 08:00AM	Cortexyme to Present at the Stifel 3rd Annual CNS Day on April 1, 2021 Business Wire
Mar-21-21 09:52PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX Newsfile
Mar-18-21 08:01PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX PR Newswire -5.33%
Mar-16-21 10:00PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX ACCESSWIRE
Mar-12-21 06:15AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX PR Newswire
Mar-10-21 08:00AM	Cortexyme to Present at the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021 Business Wire +7.29%
Mar-09-21 10:45PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX ACCESSWIRE +9.07%
Mar-08-21 08:00AM	Cortexyme Announces Partnership with Parkinson Study Group and Upcoming Alzheimers Disease Data Presentation Business Wire
Mar-07-21 05:53PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX Newsfile
Mar-03-21 03:00AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX PR Newswire
Feb-22-21 01:10PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX Newsfile
Feb-20-21 07:00PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX ACCESSWIRE
Feb-18-21 09:47PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX PR Newswire
04:45PM	Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Cortexyme, Inc. (CRTX) Investigation ACCESSWIRE
Feb-17-21 11:38AM	The Bottom Is in for These 2 Stocks? Analysts Say Buy TipRanks
Feb-16-21 08:52AM	Cortexyme Stops Enrollment In Mid-Stage Atuzaginstat Study In Alzheimer's Disease Benzinga -35.29%
Feb-15-21 09:13PM	Cortexyme Provides Regulatory Update on Development Program for Atuzaginstat in Alzheimers Disease Business Wire
Feb-10-21 04:06PM	Cortexyme Announces Leadership Appointments to Support Advancement of Atuzaginstat and Pipeline Expansion Business Wire +6.75%
Feb-08-21 08:22AM	What to Know Before Buying Cassava Sciences, the Hot Alzheimers Stock Barrons.com
12:26AM	We're Not Very Worried About Cortexyme's (NASDAQ:CRTX) Cash Burn Rate Simply Wall St.
Feb-02-21 07:32PM	2 Biotech Stocks That Could Double in 2021; Canaccord Says Buy TipRanks
Jan-26-21 08:00AM	Cortexyme Announces Pipeline Update and Anticipated 2021 Milestones Business Wire +18.00%
Jan-06-21 08:49AM	Is the Options Market Predicting a Spike in Cortexyme (CRTX) Stock? Zacks
Dec-07-20 12:49AM	Is Cortexyme (CRTX) A Good Stock To Buy Now? Insider Monkey
Dec-04-20 07:43AM	The Daily Biotech Pulse: BioCryst's Heredity Angioedema Treatment Clears FDA, Sutro Biopharma Readout, 2 IPOs Benzinga -19.62%
07:00AM	Cortexymes Phase 2/3 GAIN Trial of Atuzaginstat (COR388) in Patients with Alzheimers Disease Successfully Advances Past Interim Analysis Business Wire
Dec-01-20 08:40AM	Is the Options Market Predicting a Spike in Cortexyme (CRTX) Stock? Zacks
Nov-27-20 10:27AM	New Strong Sell Stocks for November 27th Zacks
Nov-20-20 10:45AM	New Strong Sell Stocks for November 20th Zacks
Nov-12-20 04:30PM	Cortexyme Announces Third Quarter 2020 Financial Results and Provides Business Update Business Wire
Nov-10-20 07:12AM	Are Insiders Buying Cortexyme, Inc. (NASDAQ:CRTX) Stock? Simply Wall St.
Nov-05-20 08:00AM	Cortexyme Presents an Update and Baseline Data from the Phase 2/3 GAIN Trial of Atuzaginstat at CTAD 2020, the Clinical Trials on Alzheimers Disease Conference Business Wire +5.69%
Oct-19-20 08:00AM	Cortexyme Announces Upcoming Data Presentations at November 2020 Conferences Business Wire
Sep-24-20 08:00AM	Cortexyme Announces GAIN Trial of Atuzaginstat in Alzheimers Disease Has Exceeded Study Enrollment Target of 570 Patients Business Wire
Sep-09-20 08:00AM	Cortexyme to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020 Business Wire +6.28%
Aug-27-20 08:00AM	Cortexyme Announces Issuance of Composition of Matter Patent for Atuzaginstat by the U.S. Patent and Trademark Office Business Wire
Aug-18-20 09:21AM	Company News for Aug 18, 2020 Zacks
Aug-17-20 08:00AM	Cortexyme Announces Second Quarter 2020 Financial Results and Provides Business Update Business Wire
Aug-14-20 08:00AM	Cortexyme Announces GAIN Trial of Atuzaginstat in Alzheimers Disease Has Reached Enrollment Milestone of 500 Patients Business Wire
Aug-12-20 08:11AM	We're Hopeful That Cortexyme (NASDAQ:CRTX) Will Use Its Cash Wisely Simply Wall St.
08:10AM	Here's Why We're Not Too Worried About Cortexyme's (NASDAQ:CRTX) Cash Burn Situation Simply Wall St.
Aug-06-20 04:05PM	Cortexyme Announces Webcasts of Investor Conference Presentations in August 2020 Business Wire
Jul-29-20 08:00AM	Cortexyme to Participate in Virtual Fireside Chat Hosted by LifeSci Capital on July 30, 2020 Business Wire
Jul-28-20 06:09PM	Cortexyme Presents Data Linking P. gingivalis Infection to Cardiovascular Disease Severity and Alzheimer's Disease, Along With Evidence That Treatment With Atuzaginstat (COR388) Improves Biomarkers Associated With Both Diseases Business Wire
Jul-22-20 08:00AM	Cortexyme Announces Upcoming Data Presentations at the Alzheimers Association International Conference 2020 Business Wire
Jun-14-20 07:00AM	4 Biotech Stocks That Are Seeing Big Buys in June Barrons.com
Jun-12-20 04:27PM	Hedge Funds Are Buying Cortexyme, Inc. (CRTX) Insider Monkey
Jun-09-20 08:00AM	Cortexyme Announces "Atuzaginstat" Selected as First-in-Class Nonproprietary Name for COR388 Business Wire +11.12%

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease. Cortexyme, Inc. has a partnership with Parkinson Study Group. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lynch Casey	Chief Executive Officer	Nov 18	Option Exercise	0.46	60,000	27,600	109,895	Nov 19 08:58 PM
LOWE CHRISTOPHER P.	COO & Chief Financial Officer	Nov 16	Option Exercise	2.23	30,000	66,900	90,000	Nov 16 08:17 PM
Dominy Stephen S.	Chief Scientific Officer	Nov 12	Buy	14.40	763	10,987	1,217,086	Nov 12 06:47 PM
McLoughlin Margaret	Director	Oct 08	Option Exercise	17.00	1,000	17,000	1,000	Oct 12 05:48 PM
McLoughlin Margaret	Director	Oct 08	Sale	88.93	1,000	88,930	0	Oct 12 05:48 PM
LOWE CHRISTOPHER P.	COO & Chief Financial Officer	Oct 05	Option Exercise	54.85	4,963	272,221	64,963	Oct 07 06:24 PM
LOWE CHRISTOPHER P.	COO & Chief Financial Officer	Oct 05	Sale	98.50	4,963	488,856	60,000	Oct 07 06:24 PM
LOWE CHRISTOPHER P.	COO & Chief Financial Officer	Aug 17	Option Exercise	2.23	30,000	66,900	60,000	Aug 18 05:25 PM
LOWE CHRISTOPHER P.	COO & Chief Financial Officer	Aug 16	Option Exercise	2.23	22,000	49,060	52,000	Aug 18 05:25 PM
McLoughlin Margaret	Director	Aug 16	Option Exercise	17.00	6,000	102,000	6,000	Aug 18 05:30 PM
McLoughlin Margaret	Director	Aug 16	Sale	95.44	6,000	572,644	0	Aug 18 05:30 PM
LOWE CHRISTOPHER P.	COO & Chief Financial Officer	Aug 16	Sale	95.31	22,000	2,096,779	30,000	Aug 18 05:25 PM
Detke Michael J.	Chief Medical Officer	Aug 10	Option Exercise	2.23	10,000	22,300	10,000	Aug 12 05:37 PM
Detke Michael J.	Chief Medical Officer	Aug 10	Sale	100.00	10,000	1,000,000	0	Aug 12 05:37 PM
Detke Michael J.	Chief Medical Officer	Jul 07	Option Exercise	2.23	17,400	38,802	17,400	Jul 07 08:38 PM
Detke Michael J.	Chief Medical Officer	Jul 07	Sale	55.20	17,400	960,549	0	Jul 07 08:38 PM
Detke Michael J.	Chief Medical Officer	Jul 06	Option Exercise	2.23	12,600	28,098	40,861	Jul 07 08:38 PM
Detke Michael J.	Chief Medical Officer	Jul 06	Sale	53.54	40,861	2,187,623	0	Jul 07 08:38 PM
McLoughlin Margaret	Director	Jun 28	Sale	55.15	550	30,332	0	Jun 29 05:26 PM
Lynch Casey	Chief Executive Officer	May 10	Sale	34.58	30,000	1,037,361	978,774	May 12 04:51 PM
Lamond David	Director	Mar 24	Buy	33.77	50,000	1,688,500	1,847,109	Mar 24 09:06 PM
Lynch Casey	Chief Executive Officer	Mar 22	Sale	35.59	30,000	1,067,611	1,008,774	Mar 23 07:06 PM
Lamond David	Director	Mar 04	Buy	35.34	50,000	1,767,057	1,797,109	Mar 05 05:54 PM
Lynch Casey	Chief Executive Officer	Feb 03	Sale	43.03	20,000	860,530	1,038,774	Feb 03 07:45 PM
Lynch Casey	Chief Executive Officer	Feb 02	Sale	36.21	20,000	724,102	1,058,774	Feb 03 07:45 PM
Lynch Casey	Chief Executive Officer	Feb 01	Sale	36.25	20,000	724,968	1,078,774	Feb 03 07:45 PM
Holsinger Leslie	Executive Vice President	Dec 14	Option Exercise	0.27	40,000	10,800	43,500	Dec 15 07:17 PM
Holsinger Leslie	Executive Vice President	Dec 14	Sale	30.81	40,000	1,232,528	1,800	Dec 15 07:17 PM
Holsinger Leslie	Executive Vice President	Dec 10	Option Exercise	0.27	3,500	945	3,500	Dec 14 05:16 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience